In the present study, we developed PEG-MZF-NPs/DDP/CD44-shRNA magnetic nanoliposomes and inaugurated an integrated therapy through the synergistic effect of MFH, gene therapy, and chemotherapy, and a satisfactory therapeutic effect on ovarian cancer in vitro and in vivo is shown. This evidence concerns the gene CD44 and ovarian cancer.